Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections -

TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced positive results from a large prospective trial conducted for prevention of respiratory syncytial virus (RSV). The trial compared motavizumab, the investigational monoclonal antibody (MAb) also known as Numax(R), with Synagis(R) (palivizumab), the standard of care for preventing RSV hospitalization in high-risk infants. In the Phase 3 study involving 6,635 pre-term infants at high risk for RSV, with a primary endpoint of non- inferiority, motavizumab demonstrated overall 26-percent fewer RSV hospitalizations compared with Synagis (p<0.01 for non-inferiority). Additionally, motavizumab demonstrated a statistically significant 50 percent reduction in the incidence of RSV-specific medically attended outpatient lower respiratory infections (LRIs) (p<0.01) compared with Synagis. These findings were presented today in a poster entitled, Phase 3 Trial of Motavizumab, an Enhanced Potency RSV-Specific MAb for the Prevention of Serious RSV Disease in High-Risk Infants, at the Pediatric Academic Societies' Annual Meeting in Toronto, Canada.

"As RSV continues to be the leading cause of lower respiratory tract infections in infants in the United States, we are very encouraged by the results of this Phase 3 trial, which suggest that motavizumab may help to reduce the chance that our most vulnerable babies will have serious RSV disease," said Edward M. Connor, M.D., chief medical officer and executive vice president. "Data from the study showed that motavizumab was statistically superior to Synagis for the secondary endpoint of outpatient medically attended LRI caused by RSV, and thus may reduce the overall burden of RSV disease compared to the current stan
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/4/2015)... Spanje, July 4, 2015 ... aan eerstelijns chemotherapie voor patiënten met niet-resectabele ... verlengt de progressievrije overleving in dat orgaan. ... colorectale kanker (mCRC) die alleen binnen de ... in progressievrije overleving (PFS) in de lever ...
(Date:7/3/2015)... , July 4, 2015 ... cible les épidémies que sont l,hypertension, le diabète ... du Sud-Est, par l,intermédiaire de plateformes éducatives gratuites ...      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ) ... charge le diabète en ligne , Prendre ...
(Date:7/3/2015)... July 3, 2015 According ... & Cardiac Rhythm Management Market ECG, Implantable Loop ... Implantable Cardioverter Defibrillator, Dual Chamber Pacemaker, CRT-D, CRT-P ... the global Cardiac Monitoring (CM) and Cardiac Rhythm ... $26,646.5 Million by 2020 from $21,137.7 Million in ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4
... 23, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... marketer of medical devices worldwide, today announced that its ... U.S. Food and Drug Administration (FDA). The A5 anesthesia ... is an anesthesia delivery platform that will complement Mindray,s ...
... Calif., Feb. 23, 2011 Anthera Pharmaceuticals, Inc. ... developing drugs to treat serious diseases associated with ... call to discuss the analytical method of the ... timeline of the results.Conference Call Access:Date: , February ...
Cached Medicine Technology:Mindray Announces FDA 510(k) Clearance of Its A5 Anesthesia System 2Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis 2
(Date:7/3/2015)... ... ... " Selfie on a Stick ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... , Almost every smartphone has an incredibly powerful camera built into it. And when ...
(Date:7/3/2015)... ... , ... Every year, One-to-1 Fitness and the Red Deer Fit Body ... Deer community with free fitness training and indoor fitness boot camp classes for 24 ... raised thousands of charity dollars and ended with a $10,000 donation to the Jumpstart ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to ... the first sweetFrog store located in Mississippi. The premium frozen yogurt chain was listed ... The store, located at 104 Railroad Avenue, New Albany, MS 38652, will have a ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce ... 19th sweetFrog store located in the Lone Star State. The premium frozen yogurt chain ... 2014. , The store, which opened July 1 at Duke’s Travel Plaza, is located ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... Donna Edwards (D-Md.) for her introduction of the Stop Overdose Stat (S.O.S.) Act ... by Senator Jack Reed (D-R.I.), this Act seeks to decrease drug overdose – ...
Breaking Medicine News(10 mins):Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3
... ... for the quarter ending April 30, 2009. With consistent growth and increased orders, ... ... -- Clearly Contacts released their second quarter unaudited financial results today, for the ...
... ... Dr Jav Nazemi - CEO of Igennus, manufacturer of purified omega-3 fish oil ... his business and the omega-3 EPA formula, Vegepa, which has since helped thousands ... to the Children,s Heart Federation, in order to help support the lives of ...
... On Friday the 29th of ... of Merit by the Ameican Otologic Society. The American Otological (Ear) Society was founded ... 1949. , ... On Friday the 29th of May in Phoenix, Arizona, Dr. William H. Lippy from Warren, Ohio ...
... ... Sleep Medicine in Seattle on June 5, 2009 on the subject of educating the public about ... ... meeting of the American Academy of Dental Sleep Medicine in Seattle on June 5, 2009 on ...
... time a mechanism by which nanoparticles ,cause lung damage and ... ,process involved, taking a step toward addressing the growing concerns ... science of the extremely tiny (one nanometre is one-billionth of ... annual market of around ,one trillion US dollars by 2015. ...
... Calif., June 10 IPC The Hospitalist Company, Inc. (Nasdaq: ... today that management is scheduled to present at the Jefferies 3rd ... York City. Adam Singer, M.D., Chairman and CEO, and Jeff ... IPC,s presentation will take place at 3:15 P.M. Eastern time on ...
Cached Medicine News:Health News:Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 2Health News:Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 3Health News:Omega-3 EPA: Treatment for a Heart Condition 2Health News:Omega-3 EPA: Treatment for a Heart Condition 3Health News:Omega-3 EPA: Treatment for a Heart Condition 4Health News:Omega-3 EPA: Treatment for a Heart Condition 5Health News:Omega-3 EPA: Treatment for a Heart Condition 6Health News:American Otological Society 2009 Recipient For the "Award of Merit" Goes to Dr. William H. Lippy of Warren, Ohio 2Health News:Founder of Snoring Isn't Sexy, LLC Addresses Annual Meeting of the American Academy of Dental Sleep Medicine 2Health News:Scientists advance safety of nanotechnology 2Health News:Scientists advance safety of nanotechnology 3Health News:IPC The Hospitalist Company, Inc. to Present at Jefferies 3rd Annual Healthcare Conference 2
... system utilizes a hot air drying device for ... a clear cellophane support for easy viewing. The ... flat assembly surface for the drying frame. The ... once. This 115 V, 60 Hz system includes ...
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
The 570-90 is capable of producing up to 500 volts or 2,500 milliamps. It is an excellent choice for running all types of electroblotting applications. Also ideal for PAGE, SDS-PAGE, and DNA or RNA s...
... From simple techniques such as submarine ... Multiple Step IEF, the Series 90 Programmable ... ,The Series 90 Programmable Power Supplies are ... 4000 or 6000V., All models operate in ...
Medicine Products: